Headlines from the Proactive UK newsroom.
Faron Pharmaceuticals (LON:FARN) is to expand its phase I/II MATINS clinical trial of its Clevegen cancer drug to women with ovarian cancer. Earlier this month, Faron was also given permission to expand the ongoing trial into late-stage colorectal cancer.
AFC Energy (LON:AFC) has signed a heads of agreement to collaborate with a hydrogen extraction specialist. The green hydrogen produced from their technology is a potential fuel source for AFC Energy's H-Power fuel cell systems.
Pawnbroker H&T (LON:HAT) expects results in 2019 to be at the top end of market expectations. Second half trading was strong with good performances from the acquired Money Shop and Speedloan assets.
Amigo Loans (LON:AMGO) is up for sale after its controlling shareholder said it wants to sell its 60% stake. The strategic review will consider sales of part or all of the guaranteed lender business.
Two AstraZeneca drugs have passed their latest clinical trials. Brilinta reduced the risk of further complications or death when combined with aspirin in early stage stroke sufferers while Enhertu met its survival endpoint in a phase II trial for gastric cancer.